Literature DB >> 7905831

Adaptation of the NMDA receptor in rat cortex following chronic electroconvulsive shock or imipramine.

I A Paul1, R T Layer, P Skolnick, G Nowak.   

Abstract

Chronic (14 days) administration of either imipramine or electroconvulsive shock effected significant changes in the ligand binding properties of the NMDA (N-methyl-D-aspartate) receptor complex in rat cortex. These changes were manifested as: (1) a reduction in the potency of glycine to inhibit the binding of 5,7-dichloro[3H]kynurenic acid to strychnine-insensitive glycine receptors; and (2) a reduction in the proportion of high affinity, glycine-displaceable [3H]CGP-39653 binding to NMDA receptors. Chronic electroconvulsive shock, but not imipramine treatment also reduced the density of [3H]CGP-39653 binding sites in cortical membranes. These findings demonstrate that the ability of chronic antidepressant treatments to induce adaptive changes in the glycine and glutamate regulatory sites of the NMDA receptor is not species specific, since it obtains in rats as well as mice.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7905831     DOI: 10.1016/0922-4106(93)90199-j

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  13 in total

Review 1.  Targeting the glutamatergic system to treat major depressive disorder: rationale and progress to date.

Authors:  Daniel C Mathews; Ioline D Henter; Carlos A Zarate
Journal:  Drugs       Date:  2012-07-09       Impact factor: 9.546

2.  Reduced metabotropic glutamate receptor 5 in the Flinders Sensitive Line of rats, an animal model of depression: an autoradiographic study.

Authors:  Tomislav Kovačević; Ivan Skelin; Luciano Minuzzi; Pedro Rosa-Neto; Mirko Diksic
Journal:  Brain Res Bull       Date:  2012-01-31       Impact factor: 4.077

Review 3.  Modulation of ligand-gated ion channels by antidepressants and antipsychotics.

Authors:  Gerhard Rammes; Rainer Rupprecht
Journal:  Mol Neurobiol       Date:  2007-04       Impact factor: 5.590

Review 4.  Ketamine: promising path or false prophecy in the development of novel therapeutics for mood disorders?

Authors:  Gerard Sanacora; Alan F Schatzberg
Journal:  Neuropsychopharmacology       Date:  2014-09-26       Impact factor: 7.853

5.  Sigma receptors [σRs]: biology in normal and diseased states.

Authors:  Colin G Rousseaux; Stephanie F Greene
Journal:  J Recept Signal Transduct Res       Date:  2015-06-09       Impact factor: 2.092

6.  Chronic dosing with 1-aminocyclopropanecarboxylic acid, a glycine partial agonist, modulates NMDA inhibition of muscarinic-coupled PI hydrolysis in rat cortical slices.

Authors:  K M Boje; S S Lakhman
Journal:  Neurochem Res       Date:  1998-09       Impact factor: 3.996

Review 7.  Trends in the development of new antidepressants. Is there a light at the end of the tunnel?

Authors:  Pal Pacher; Valeria Kecskemeti
Journal:  Curr Med Chem       Date:  2004-04       Impact factor: 4.530

8.  Antidepressants are a rational complementary therapy for the treatment of Alzheimer's disease.

Authors:  Marwa Aboukhatwa; Laura Dosanjh; Yuan Luo
Journal:  Mol Neurodegener       Date:  2010-03-12       Impact factor: 14.195

Review 9.  Innovative approaches for the development of antidepressant drugs: current and future strategies.

Authors:  Lee E Schechter; Robert H Ring; Chad E Beyer; Zoë A Hughes; Xavier Khawaja; Jessica E Malberg; Sharon Rosenzweig-Lipson
Journal:  NeuroRx       Date:  2005-10

Review 10.  Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders.

Authors:  Gerard Sanacora; Carlos A Zarate; John H Krystal; Husseini K Manji
Journal:  Nat Rev Drug Discov       Date:  2008-05       Impact factor: 84.694

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.